Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.

Avery KN, Metcalfe C, Vedhara K, Lane JA, Davis M, Neal DE, Hamdy FC, Donovan JL, Blazeby JM.

Eur Urol. 2012 Oct;62(4):649-55. doi: 10.1016/j.eururo.2011.12.059. Epub 2012 Jan 10.

PMID:
22244151
2.

Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.

Thomas R, Glasziou P, Rychetnik L, Mackenzie G, Gardiner R, Doust J.

BMJ Open. 2014 Dec 24;4(12):e005691. doi: 10.1136/bmjopen-2014-005691.

3.

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?

Avery KN, Metcalfe C, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL.

BJU Int. 2008 Dec;102(11):1629-33. doi: 10.1111/j.1464-410X.2008.07879.x. Epub 2008 Aug 14.

4.

Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.

Howard K, Salkeld GP, Patel MI, Mann GJ, Pignone MP.

Health Expect. 2015 Dec;18(6):3123-35. doi: 10.1111/hex.12301. Epub 2014 Nov 10.

PMID:
25382490
5.

Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.

Watson E, Hewitson P, Brett J, Bukach C, Evans R, Edwards A, Elwyn G, Cargill A, Austoker J.

Patient Educ Couns. 2006 Nov;63(3):367-79. Epub 2006 Jul 27.

PMID:
16875796
6.

Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure.

Carey M, Bryant J, Yoong SL, Russell G, Barker D, Sanson-Fisher R.

BMC Fam Pract. 2013 Dec 9;14:186. doi: 10.1186/1471-2296-14-186.

7.

The relationship between prostate cancer knowledge and beliefs and intentions to attend PSA screening among at-risk men.

Hevey D, Pertl M, Thomas K, Maher L, Chuinneagáin SN, Craig A.

Patient Educ Couns. 2009 Feb;74(2):244-9. doi: 10.1016/j.pec.2008.08.013. Epub 2008 Oct 10.

PMID:
18848753
8.

Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.

Evans R, Joseph-Williams N, Edwards A, Newcombe RG, Wright P, Kinnersley P, Griffiths J, Jones M, Williams J, Grol R, Elwyn G.

J Med Internet Res. 2010 Aug 6;12(3):e27. doi: 10.2196/jmir.1305.

9.
10.

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.

Brindle LA, Oliver SE, Dedman D, Donovan JL, Neal DE, Hamdy FC, Lane JA, Peters TJ.

BJU Int. 2006 Oct;98(4):777-82.

11.

Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.

Avery KN, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL.

Eur Urol. 2008 Jun;53(6):1186-93. Epub 2007 Aug 15.

PMID:
17709169
12.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2015 Jul;68(1):139-46. doi: 10.1016/j.eururo.2014.08.010. Epub 2014 Aug 20.

13.

Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).

Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.

J Med Assoc Thai. 2006 Jan;89(1):37-42.

PMID:
16583579
14.

Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.

Hayat Roshanai A, Nordin K, Berglund G.

Acta Oncol. 2013 Nov;52(8):1602-8. doi: 10.3109/0284186X.2012.762998. Epub 2013 Feb 19.

PMID:
23421929
15.
16.

Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.

van Vugt HA, Roobol MJ, Venderbos LD, Joosten-van Zwanenburg E, Essink-Bot ML, Steyerberg EW, Bangma CH, Korfage IJ.

Eur J Cancer. 2010 Feb;46(3):669-77. doi: 10.1016/j.ejca.2009.11.022.

PMID:
20022239
17.

A comparison of US and Australian men's values and preferences for PSA screening.

Howard K, Brenner AT, Lewis C, Sheridan S, Crutchfield T, Hawley S, Nielsen ME, Pignone MP.

BMC Health Serv Res. 2013 Oct 5;13:388. doi: 10.1186/1472-6963-13-388.

18.

Factors influencing Nigerian men's decision to undergo prostate specific antigen testing.

Enaworu OU, Khutan R.

Afr Health Sci. 2016 Jun;16(2):524-32. doi: 10.4314/ahs.v16i2.21.

19.

Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in black American men.

Woods VD, Montgomery SB, Herring RP, Gardner RW, Stokols D.

J Natl Med Assoc. 2006 Apr;98(4):492-504. Review.

20.

Supplemental Content

Support Center